As we mark three years since the start of the large-scale Russian invasion of Ukraine, I believe it is timely to take stock ...

Phase 1b US study planned for 2026, as company competes with NS Pharma and Avidity Biosciences in exon 44 space ...

Entrada Therapeutics is finally able to get its Duchenne muscular dystrophy candidate (DMD) back on track after the FDA ...

Entrada Therapeutics gains FDA clearance for its Phase 1b ELEVATE-44-102 study, evaluating ENTR-601-44 in adult Duchenne ...

In a report released today, Boobalan Pachaiyappan from Roth MKM reiterated a Buy rating on Entrada Therapeutics Inc (TRDA – Research Report), ...

Receives FDA authorization to initiate ELEVATE-44-102, a Phase 1b multiple ascending dose clinical study of ENTR-601-44 in adults living with Duchenne muscular dystrophy - - Follows recently received ...

Entrada Therapeutics (TRDA) announced that the United States Food and Drug Administration has lifted the clinical hold on ENTR-601-44 and ...

Receives FDA authorization to initiate ELEVATE-44-102, a Phase 1b multiple ascending dose clinical study of ENTR-601-44 in adults living with Duchenne muscular dystrophy – – Follows recently received ...

New rivalries, fresh faces, line-up changes and much more. Gear up for Buriram as MotoGP blasts back into action ...

WASHINGTON — After nearly three years operating in stealth mode, Seattle-based startup Kapta Space emerged on Feb. 21, announcing plans to demonstrate metasurface antenna technology for space-based ...

Kapta Space plans to innovate space radar technology, enhancing precision and reducing imaging costs with electronically ...

Oswaldo Rivas Reubicarán la Entrada Peatonal de la Garita de Calexico ...